Wednesday February 21st 2018

Clinical and MRI characterization of MS patients with a pure and severe cognitive onset

Cognitive impairment affects approximately half of multiple sclerosis (MS) patients during the course of the disease[1]. It is a frequently overlooked clinical manifestation of MS, although it affects deleteriously social and vocational activities, and often results in unemployment[2,3], thus reducing an individual’s independence. Neuropsychological abnormalities may be detected in all MS populations including pediatric MS[4], and at all stages including clinically isolated syndromes (CIS) [5] and radiologically isolated syndromes (RIS)[6,7]. (Source: Clinical Neurology and Neurosurgery)

Link to original:

Clinical and MRI characterization of MS patients with a pure and severe cognitive onset

Leave a Comment

More from category

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]

Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…
Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…

Subtle gait and balance dysfunction is a precursor to loss of mobility in multiple sclerosis (MS). Biomechanical [Read More]

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]